These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27837170)

  • 1. Differential contributions of vasopressin V1A and oxytocin receptors in the amygdala to pain-related behaviors in rats.
    Cragg B; Ji G; Neugebauer V
    Mol Pain; 2016; 12():. PubMed ID: 27837170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal application of neuropeptide S inhibits arthritis pain-related behaviors through an action in the amygdala.
    Medina G; Ji G; Grégoire S; Neugebauer V
    Mol Pain; 2014 May; 10():32. PubMed ID: 24884567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors.
    Palazzo E; Fu Y; Ji G; Maione S; Neugebauer V
    Neuropharmacology; 2008 Sep; 55(4):537-45. PubMed ID: 18533199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala.
    Ji G; Fu Y; Ruppert KA; Neugebauer V
    Mol Pain; 2007 Jun; 3():13. PubMed ID: 17550594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT2CR blockade in the amygdala conveys analgesic efficacy to SSRIs in a rat model of arthritis pain.
    Grégoire S; Neugebauer V
    Mol Pain; 2013 Aug; 9():41. PubMed ID: 23937887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amygdala group II mGluRs mediate the inhibitory effects of systemic group II mGluR activation on behavior and spinal neurons in a rat model of arthritis pain.
    Mazzitelli M; Neugebauer V
    Neuropharmacology; 2019 Nov; 158():107706. PubMed ID: 31306647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain.
    Thompson JM; Ji G; Neugebauer V
    Mol Pain; 2015 Aug; 11():51. PubMed ID: 26311432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior.
    Fu Y; Neugebauer V
    J Neurosci; 2008 Apr; 28(15):3861-76. PubMed ID: 18400885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxytocin and vasopressin in the medial amygdala differentially modulate approach and avoidance behavior toward illness-related social odor.
    Arakawa H; Arakawa K; Deak T
    Neuroscience; 2010 Dec; 171(4):1141-51. PubMed ID: 20933576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
    Chan WY; Wo NC; Manning M
    Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mGluR1 and mGluR5 antagonists in the amygdala inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain.
    Han JS; Neugebauer V
    Pain; 2005 Jan; 113(1-2):211-22. PubMed ID: 15621382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
    Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
    Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
    Akerlund M; Bossmar T; Brouard R; Kostrzewska A; Laudanski T; Lemancewicz A; Serradeil-Le Gal C; Steinwall M
    Br J Obstet Gynaecol; 1999 Oct; 106(10):1047-53. PubMed ID: 10519430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomethyl fumarate inhibits pain behaviors and amygdala activity in a rat arthritis model.
    Kim H; Thompson J; Ji G; Ganapathy V; Neugebauer V
    Pain; 2017 Dec; 158(12):2376-2385. PubMed ID: 28832396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.
    Wigger A; Sánchez MM; Mathys KC; Ebner K; Frank E; Liu D; Kresse A; Neumann ID; Holsboer F; Plotsky PM; Landgraf R
    Neuropsychopharmacology; 2004 Jan; 29(1):1-14. PubMed ID: 12942143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement.
    Everett NA; McGregor IS; Baracz SJ; Cornish JL
    Neuropharmacology; 2018 May; 133():1-11. PubMed ID: 29353054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxytocin alleviates orofacial mechanical hypersensitivity associated with infraorbital nerve injury through vasopressin-1A receptors of the rat trigeminal ganglia.
    Kubo A; Shinoda M; Katagiri A; Takeda M; Suzuki T; Asaka J; Yeomans DC; Iwata K
    Pain; 2017 Apr; 158(4):649-659. PubMed ID: 28072605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
    Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA
    Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat.
    Mak P; Broussard C; Vacy K; Broadbear JH
    J Psychopharmacol; 2012 Apr; 26(4):532-42. PubMed ID: 21890582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
    Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
    Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.